Status:
TERMINATED
Eye Tracking as a Biomarker of Cannabis Effects
Lead Sponsor:
New York State Psychiatric Institute
Conditions:
Cannabis Use
Pain, Acute
Eligibility:
All Genders
21-55 years
Phase:
PHASE2
Brief Summary
Biomarkers of recent drug use and intoxication have societal relevance, in that they are used by law enforcement and other agencies to detect drug impairment. For instance, a breathalyzer can quickly ...
Eligibility Criteria
Inclusion
- Males/non-pregnant females
- Report smoking cannabis ≥1 day per week
- Able to perform all study procedures
Exclusion
- Meeting DSM-V criteria for severe substance use
- Use of illicit drugs ≥1 day/week in the prior 4 weeks
- Abnormality with the eyes which may affect the eye tracking technology such as color blindness, naturally occurring nystagmus, amblyopia, strabismus, age-related macular degeneration (AMD), cataract, diabetic eye disease, glaucoma, dry eye, extreme refractive error, bacterial or viral infections of the eye
- 7\. User of supplemental oxygen
Key Trial Info
Start Date :
October 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 31 2020
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT04100590
Start Date
October 1 2019
End Date
January 31 2020
Last Update
June 30 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
New York State Psychiatric Institute
New York, New York, United States, 10032